Sunday, 12 July, 2020
Exclusives - 13 May, 2020

India's Jubilant Life signs licensing deal for Gilead's Remdesivir COVID-19 drug

India’s Jubilant Life Sciences Ltd has signed a non-exclusive licensing agreement for selling Gilead Sciences Inc’s COVID-19 treatment Remdesivir in 127 countries... #LicencingdealforGilead'sRemdesivir...

India’s Jubilant Life Sciences Ltd said on Tuesday it had signed a non-exclusive licensing agreement for selling Gilead Sciences Inc’s experimental COVID-19 treatment Remdesivir in 127 countries, including India.

Gilead earlier this month received the US Food and Drug Administration’s emergency use authorisation for using Remdesivir as a treatment against COVID-19, the respiratory illness caused by the novel coronavirus, after the drug-maker provided data showing the drug had helped patients.

Source: Reuters

Bhopal - The City of Lakes
HOTELS & RESTAURANTS
COLLEGES
ART & CULTURE
MAJOR TOURIST ATTRACTIONS
TECHNICAL UNIVERSITIES & INSTITUTIONS
MEDICAL COLLEGES & HOSPITALS
UNIVERSITIES & ACADEMIES
SCHOOLS
INDUSTRIAL HOUSES
 
Tourist Attractions in M.P.
NATIONAL PARKS AND WILDLIFE SANCTUARIES
HISTORICAL & ARCHAEOLOGICAL IMPORTANT PLACES
HERITAGES & MONUMENTS
HOLY CITIES
HILL RESORTS